Borosil Scienti. (BOROSCI)
Fast GrowerFairStock Score: 38/100 — MIXED
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹133.92 |
| Market Cap | ₹1,191.18 Cr |
| P/E Ratio | 27.61 |
| ROCE | 10.31% |
| ROE | 8.13% |
| Dividend Yield | 0% |
| Profit Growth | 132.49% |
| Debt/Equity | 0.02 |
| Sales Growth | 11.2% |
| Promoter Holding | 67.81% |
| 52-Week Range | ₹96.64 — ₹181.25 |
| Sector | Industrial Products |
| Book Value | ₹49.63 |
Strengths
- Very low leverage with Debt/Equity of 0.02.
- High promoter holding of 67.81% aligns shareholder interest.
- Sales growth of 19.57% shows decent demand traction.
- Piotroski F-Score of 7/9 indicates sound recent fundamentals.
- PEG of 0.51 suggests growth is not excessively priced if sustained.
Concerns
- P/E of 38.74 is expensive against current earnings.
- ROE of 8.13% and ROCE of 10.31% are mediocre returns on capital.
- Zero dividend yield means no income support for investors.
- Profit growth of 132.49% may be a low-base effect and could normalize.
AI Analysis
At ₹116.60, Borosil Scienti is valued at ₹922 crore. That means I am paying 38.7 times trailing earnings and 2.6 times book value for a business earning only an 8.13% return on equity. Benjamin Graham would call that a lack of margin of safety. The balance sheet is clean—debt is just 0.02 times equity—and promoter holding of 67.81% is reassuring. Sales grew 19.57%, and reported profit jumped 132.49%. Such a number catches attention, but I must ask: sustainable, or a low-base recovery? In the latest quarter, net profit of ₹9 crore on sales of ₹121 crore is only about a 7.4% margin. A PEG of 0.51 assumes that high profit growth continues; if it normalizes, the P/E of 38.74 becomes uncomfortable. Piotroski F-score of 7 tells me recent fundamentals are sound, but the score grades past financial health, not future moat. No dividend means total return depends entirely on capital gains, and the stock has already fallen from ₹181.25 to ₹116.60. I like the low debt, the aligned promoter, and the double-digit sales growth, but I do not like paying 38 times earnings for a 10.31% ROCE. This is a decent growth story at a demanding price, not a wonderful business at a fair price. I would wait for either a cheaper price or proof that returns on capital can move meaningfully above current levels. FairStock's mixed 38/100 matches my instinct: watch, but do not chase.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer